13F Pro

SEC Form 4 reporting owner

Kenkare-Mitra Sara

Kenkare-Mitra Sara has filed 3 Form 4 transactions reported between December 3, 2025 and May 14, 2026, as Director of Unicycive Therapeutics, Inc. and President and Head of R&D of Alector, Inc..

Name as filed: Kenkare-Mitra Sara

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$47K
1 lines
Companies
2
with Form 4 filings
Latest transaction
May 14, 2026
transaction date

Roles and reported holdings

  • UNCYUnicycive Therapeutics, Inc.
    May 14, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • ALECAlector, Inc.
    Dec 3, 2025

    President and Head of R&D

    Held directly501,652 sh as of Dec 3, 2025 · Form 4

    24 months: $47K sold

Transaction history

All 3 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
May 14, 2026UNCYDirectorGrant or awardCode A · direct42,100—Form 4
May 14, 2026UNCYDirectorGrant or awardCode A · direct84,200—Form 4
Dec 3, 2025ALECPresident and Head of R&DOpen-market saleCode S · direct41,687$47K@ $1.12Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.